Tucson Morning Blend


New hope for patients fighting rare, aggressive cancer

Posted: 3:13 PM, Mar 12, 2020
Updated: 2020-03-12 18:13:51-04

Cancer is a disease that almost all of us will face at some point in our lives, either personally or with a loved one, but it’s not usually something we are faced with when we’re in the prime of our lives. Epithelioid sarcoma (ES) is an extremely rare, aggressive form of soft tissue cancer that often occurs in otherwise healthy young adults

(20s-40s). Given that ES often appears as a painless growth or lump, it can be difficult to diagnose or patients may experience a delay in diagnosis.

Until now, there were no treatments specifically for this rare type of cancer. But with the recent accelerated approval by the FDA of TAZVERIK™ (tazemetostat) for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection, ES patients have a new treatment option to discuss with their physicians. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). For more information on TAZVERIK, including full Prescribing Information, please visit: www.tazverik.com [tazverik.com].

Victor Villalobos, M.D., Ph.D. is a medical oncologist specializing in the treatment and management of soft tissue and bone sarcomas. His clinical research focuses on the development and participation in clinical trials for the
treatment of soft tissue sarcomas. He is the Director of Sarcoma Medical Oncology and Assistant Professor of Medicine-Medical Oncology at the University of Colorado School of Medicine. Dr. Villalobos received his M.D.
and Ph.D. from Washington University in St. Louis School of Medicine in 2008.

Sandra Griego first noticed something was wrong when she lost use of her left arm, which impacted her job as a daycare provider for young children. She was diagnosed at Stage 3 with a rare cancer called epithelioid sarcoma. Sandra lives in the greater Denver area.